Cargando…

1583. Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin

BACKGROUND: Oritavancin (ORI) is a potent lipoglycopeptide with desirable PK/PD parameters for treating serious gram-positive infections. This study assessed the activity of ORI against Staphylococcus aureus (SA), Enterococcus faecalis (EF), and E. faecium (EFM) causing bloodstream infection (BSI),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalhaes, Cecilia G, Sader, Helio S, Streit, Jennifer M, Flamm, Robert K, Mendes, Rodrigo E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810100/ http://dx.doi.org/10.1093/ofid/ofz360.1447

Ejemplares similares

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)
por: Carvalhaes, Cecilia G., et al.
Publicado: (2022)

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

470 Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia
por: Narayanan, Navaneeth, et al.
Publicado: (2019)

327. Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infections in European Hospitals (2010–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

646. Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?
por: Peghin, Maddalena, et al.
Publicado: (2019)

1629. Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

A rationale for combination ampicillin and daptomycin in renal transplant patients with enterococcal infective endocarditis
por: Castro-Lainez, Miriams Teresita, et al.
Publicado: (2018)

Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis
por: Chuang, Yu-Chung, et al.
Publicado: (2014)

Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a daptomycin-containing regimen
por: Beneri, Christy A, et al.
Publicado: (2008)

De Novo Daptomycin-Nonsusceptible Enterococcal Infections
por: Kelesidis, Theodoros, et al.
Publicado: (2012)

The effects of daptomycin on cell wall biosynthesis in Enterococcal faecalis
por: Rimal, Binayak, et al.
Publicado: (2023)

2192. Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia when Tested against Tazobactam Combinations
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

Clinical Features and Rate of Infective Endocarditis in Non-Faecalis and Non-faecium Enterococcal Bacteremia
por: Jang, Hee-Chang, et al.
Publicado: (2011)

A potential role for daptomycin in enterococcal infections: what is the evidence?
por: Cantón, Rafael, et al.
Publicado: (2010)

Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin
por: Bamberger, David M
Publicado: (2007)

729 Activity of Ceftaroline and Comparator Agents Tested against Staphylococcus aureus from Patients with Bacteremia in United States (USA) Medical Centers (2009-2013)
por: Sader, Helio S., et al.
Publicado: (2014)

622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS)
por: Simar, Shelby, et al.
Publicado: (2019)

1081. Antimicrobial Activity of Dalbavancin Tested Against Gram-Positive Organisms Isolated From Patients With Infective Endocarditis in United States and European Medical Centers
por: Sader, Helio S, et al.
Publicado: (2018)

2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018
por: Sader, Helio S, et al.
Publicado: (2019)

333. Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
por: Huband, Michael D, et al.
Publicado: (2017)

Enterococcal Endocarditis: Hiding in Plain Sight
por: Barnes, Aaron M. T., et al.
Publicado: (2021)

Crescentic Glomerulonephritis Due to Enterococcal Endocarditis
por: Klarić, Dragan, et al.
Publicado: (2023)

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
por: Sader, Helio S, et al.
Publicado: (2017)

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial
por: Pujol, Miquel, et al.
Publicado: (2020)

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions
por: Pfaller, Michael A., et al.
Publicado: (2017)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
por: Stewart, Cassie L., et al.
Publicado: (2017)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)
por: Mendes, R. E., et al.
Publicado: (2017)

1000. Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated From Patients Hospitalized With Bacteremia in United States and European Medical Centers: Results From the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2018)

Disposition of linezolid or daptomycin in Enterococcal bloodstream infections according to vancomycin resistant Enterococcus colonization
por: Short, Elizabeth, et al.
Publicado: (2014)

Retrospective Study of Linezolid vs. Daptomycin for the Treatment of Vancomycin--resistant Enterococcal Bloodstream Infection
por: Rai, Rena, et al.
Publicado: (2017)

1045 Linezolid Compared to Daptomycin for the Treatment of Vancomycin-resistant Enterococcal Urinary Tract Infections
por: Moenster, Ryan P., et al.
Publicado: (2014)

1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)
por: Avery, Lindsay, et al.
Publicado: (2018)

Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis
por: Johnson, Jennifer A., et al.
Publicado: (2015)

Enterococcal meningitis/ventriculitis in Qatar—Experience with eight patients
por: Yousef Khan, Fahmi
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ljou5lqjshg3kvdshkn36s2nlq